Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
ZOLMITRIPTAN
SANDOZ CANADA INCORPORATED
N02CC03
ZOLMITRIPTAN
2.5MG
TABLET
ZOLMITRIPTAN 2.5MG
ORAL
3/6
Prescription
SELECTIVE SEROTONIN AGONISTS
Active ingredient group (AIG) number: 0134381001; AHFS:
APPROVED
2011-06-07
_ _ _Sandoz Zolmitriptan and Sandoz Zolmitriptan ODT _ _Page 1 of 45_ PRODUCT MONOGRAPH PR SANDOZ ZOLMITRIPTAN Zolmitriptan 2.5 mg Tablet PR SANDOZ ZOLMITRIPTAN ODT Zolmitriptan 2.5 mg Orally Disintegrating Tablet 5-HT 1 Receptor Agonist MIGRAINE THERAPY Sandoz Canada Inc. 110 Rue de Lauzon, Boucherville, QC J4B 1E6 Date of Revision: March 2, 2020 Submission Control No: 236320 _ _ _Sandoz Zolmitriptan and Sandoz Zolmitriptan ODT _ _Page 2 of 45_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 5 ADVERSE REACTIONS ................................................................................................. 11 DRUG INTERACTIONS ................................................................................................. 18 DOSAGE AND ADMINISTRATION ............................................................................. 19 OVERDOSAGE ............................................................................................................... 21 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 21 STORAGE AND STABILITY ......................................................................................... 24 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 24 PART II: SCIENTIFIC INFORMATION .............................................................................. 26 PHARMACEUTICAL INFORMATION ......................................................................... 26 CLINICAL TRIALS ...................................... Կարդացեք ամբողջական փաստաթուղթը